博济医药：股东合计计划减持公司股份不超过约1149万股

Group 1 - The core revenue composition of Boji Pharmaceutical for the year 2024 is 99.39% from services and 0.61% from sales [1] - The controlling shareholder, Wang Tingchun, holds approximately 119 million shares, representing 30.99% of the total share capital after excluding repurchased shares [3] - The company plans to reduce its shares by up to approximately 11.49 million shares, which is 3% of the total share capital after excluding repurchased shares, through block trading or centralized bidding within three months [3]